Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 2/20 | 0.34 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.33 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23920419 | 0.92 | TLR8 (0.37) | TLR8TLR7NOS1TBXAS1DAO | |
| SCHEMBL23139161 | 0.82 | NOS1 (0.36) | TLR8TLR7NOS1TBXAS1 | |
| SCHEMBL6114716 | 0.81 | TBXAS1 (0.47) | TLR8TLR7NOS1TBXAS1DAO | |
| SCHEMBL6114927 | 0.81 | TBXAS1 (0.47) | TLR8TLR7NOS1TBXAS1DAO | |
| SCHEMBL11438392 | 0.81 | TBXAS1 (0.47) | TLR8TLR7NOS1TBXAS1DAO | |
| SCHEMBL11440961 | 0.81 | TBXAS1 (0.47) | TLR8TLR7NOS1TBXAS1DAO | |
| SCHEMBL5691507 | 0.81 | TBXAS1 (0.47) | TLR8TLR7NOS1TBXAS1DAO | |
| SCHEMBL6114640 | 0.81 | TBXAS1 (0.47) | TLR8TLR7NOS1TBXAS1DAO | |
| SCHEMBL6114991 | 0.81 | TBXAS1 (0.47) | TLR8TLR7NOS1TBXAS1DAO | |
| SCHEMBL3312967 | 0.81 | TBXAS1 (0.47) | TLR8TLR7NOS1TBXAS1DAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043621-B2 | Small molecule inhibitors of Interleukin-4 | TRUSTEES OF BOSTON UNIVERSITY (US) | 2024-07-23 | — | — | US | disclosed |
| US-20210317114-A1 | SMALL MOLECULE INHIBITORS OF INTERLEUKIN-4 | TRUSTEES OF BOSTON UNIVERSITY (US) | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12043621-B2 | Small molecule inhibitors of Interleukin-4 | IL4, IL2, IL4I1 | TLR8 717/4885TLR7 1121/4885NOS1 2110/4885 |
| US-20210317114-A1 | SMALL MOLECULE INHIBITORS OF INTERLEUKIN-4 | IL4, IL2, IL4I1 | TLR8 717/4885TLR7 1121/4885NOS1 2110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.